TAP deficiency syndrome

Bare lymphocyte syndrome (BLS) is characterized by a severe down-regulation of HLA class I and/or class II molecules. In type 1 BLS the defect is confined to HLA class I molecules, while in type 2 BLS HLA class II molecules are down-regulated [1]. Characterization of 22 patients with type 1 BLS over the last 22 years has revealed the existence of several clinically and immunologically distinct disease subsets [1–20]. In this review we will focus on a recently characterized group of patients with a distinct disease phenotype due to a defective TAP complex, the peptide transporter complex associated with antigen presentation [2–15]. We will describe clinical manifestations and immunological findings of patients suffering from TAP deficiency syndrome, and discuss the differential diagnosis and therapeutic options.

[1]  J. Zimmer,et al.  Inefficient protection of human TAP‐deficient fibroblasts from autologous NK cell‐mediated lysis by cytokines inducing HLA class I expression , 1999, European journal of immunology.

[2]  R. Hertz,et al.  WEGENER'S GRANULOMATOSIS. , 1963, The American journal of medicine.

[3]  L. Notarangelo,et al.  Defective expression of HLA class I and CD1a molecules in boy with Marfan-like phenotype and deep skin ulcers. , 1996, Journal of the American Academy of Dermatology.

[4]  Guy Hoffman,et al.  Wegener Granulomatosis: An Analysis of 158 Patients , 1992, Annals of Internal Medicine.

[5]  A. Zvulunov,et al.  Cutaneous granulomas as a presenting sign in ataxia-telangiectasia. , 1997, Dermatology.

[6]  Shinichi Watanabe,et al.  Immunohistochemical studies of major histocompatibility antigens in a case of the bare lymphocyte syndrome without immunodeficiency. , 1987, Journal of the American Academy of Dermatology.

[7]  L. Lanier,et al.  Inhibitory MHC class I receptors on NK cells and T cells. , 1996, Immunology today.

[8]  H. Bétuel,et al.  Combined immunodeficiency disease associated with absence of cell-surface HLA-A and -B antigens. , 1978, The Journal of pediatrics.

[9]  J. Bell,et al.  HLA-E binds to natural killer cell receptors CD94/NKG2A, B and C , 1998, Nature.

[10]  H. Boehmer,et al.  Positive selection of antigen-specific T cells in thymus by restricting MHC molecules , 1988, Nature.

[11]  Z. Han,et al.  Thrombocytopoietic effect of heparin given in chronic immune thrombocytopenic purpura , 1995, The Lancet.

[12]  P. Schellekens,et al.  Failure of lymphocyte-membrane HLA-A and -B expression in two siblings with combined immunodeficiency. , 1979, Clinical immunology and immunopathology.

[13]  Patricia Woo,et al.  Oxford textbook of rheumatology , 1995 .

[14]  N. Morrice,et al.  A role for the thiol-dependent reductase ERp57 in the assembly of MHC class I molecules , 1998, Current Biology.

[15]  V. Cerundolo,et al.  Association of a syndrome resembling Wegener's granulomatosis with low surface expression of HLA class-I molecules , 1999, The Lancet.

[16]  V. A. Lisovskii,et al.  [Wegener's granulomatosis]. , 1972, Klinicheskaia meditsina.

[17]  Chyung-Ru Wang,et al.  Susceptibility of Mice Deficient in CD1D or TAP1 to Infection with Mycobacterium tuberculosis , 1999, The Journal of experimental medicine.

[18]  F. Brodsky,et al.  "Bare lymphocytes" without immunodeficiency. , 1983, Human immunology.

[19]  M. G. Fleming,et al.  Caseating cutaneous granulomas in a patient with X-linked infantile hypogammaglobulinemia. , 1991, Journal of the American Academy of Dermatology.

[20]  K. Ohnishi,et al.  Differential regulation of formation of multinucleated giant cells from concanavalin A-stimulated human blood monocytes by IFN-gamma and IL-4. , 1993, Journal of immunology.

[21]  R. Welsh,et al.  Control of infections by NK cells. , 1998, Current topics in microbiology and immunology.

[22]  Chronic granulomatous disease in adults , 1996, The Lancet.

[23]  J. Touraine.  THE BARE-LYMPHOCYTE SYNDROME: REPORT ON THE REGISTRY , 1981, The Lancet.

[24]  P. Cresswell,et al.  Presentation of viral antigen controlled by a gene in the major histocompatibility complex , 1990, Nature.

[25]  P. Cresswell,et al.  Mechanisms of MHC class I--restricted antigen processing. , 1998, Annual review of immunology.

[26]  V. Cerundolo,et al.  A case of primary immunodeficiency due to a defect of the major histocompatibility gene complex class I processing and presentation pathway. , 1997, Immunology letters.

[27]  K. Sullivan,et al.  Molecular analysis of the bare lymphocyte syndrome. , 1985, The Journal of clinical investigation.

[28]  P. McCracken,et al.  Letter: Tennis elbow. , 1974 .

[29]  J. Gustafson,et al.  Cystic Fibrosis , 2009, Journal of the Iowa Medical Society.

[30]  Y. Sugiyama,et al.  Progressive sinobronchiectasis associated with the "bare lymphocyte syndrome" in an adult. , 1986, Chest.

[31]  R. Deremee.  Concise Review for Primary-Care PhysiciansSarcoidosis , 1995 .

[32]  P. Cresswell,et al.  The thiol oxidoreductase ERp57 is a component of the MHC class I peptide-loading complex , 1998, Current Biology.

[33]  J P Cazenave,et al.  Human peptide transporter deficiency: importance of HLA-B in the presentation of TAP-independent EBV antigens. , 1997, Journal of immunology.

[34]  J. Salamero,et al.  Homozygous human TAP peptide transporter mutation in HLA class I deficiency. , 1994, Science.

[35]  A. McMichael,et al.  HLA and MHC: Genes, Molecules And Function , 1997, Nature Medicine.

[36]  H. Ljunggren,et al.  In search of the 'missing self': MHC molecules and NK cell recognition. , 1990, Immunology today.

[37]  I. Florianová,et al.  [Midline granuloma]. , 1990, Casopis lekaru ceskych.

[38]  H. Ljunggren,et al.  Association of class I major histocompatibility heavy and light chains induced by viral peptides , 1989, Nature.

[39]  J. Zimmer,et al.  Activity and Phenotype of Natural Killer Cells in Peptide Transporter (TAP)-deficient Patients (Type I Bare Lymphocyte Syndrome) , 1998, The Journal of experimental medicine.

[40]  V. Rodríguez-Valverde,et al.  Clinical features and outcome of 95 patients with hypersensitivity vasculitis. , 1997, The American journal of medicine.

[41]  K. Tadokoro,et al.  Cell surface expression of HLA-E molecules on PBMC from a TAP1-deficient patient. , 1999, Tissue antigens.

[42]  H. de la Salle,et al.  Association of HLA class I antigen deficiency related to a TAP2 gene mutation with familial bronchiectasis. , 1995, The Journal of pediatrics.

[43]  K. Tadokoro,et al.  Splice acceptor site mutation of the transporter associated with antigen processing-1 gene in human bare lymphocyte syndrome. , 1999, The Journal of clinical investigation.

[44]  P. Cresswell,et al.  Roles for calreticulin and a novel glycoprotein, tapasin, in the interaction of MHC class I molecules with TAP. , 1996, Immunity.

[45]  Mark M. Davis,et al.  The nature of major histocompatibility complex recognition by γδ T cells , 1994, Cell.

[46]  M. Colonna.  Specificity and function of immunoglobulin superfamily NK cell inhibitory and stimulatory receptors , 1997, Immunological reviews.

[47]  A. Plebani,et al.  HLA class I deficiencies due to mutations in subunit 1 of the peptide transporter TAP1. , 1999, The Journal of clinical investigation.

[48]  T. Mayadas,et al.  P-selectin deficiency exacerbates experimental glomerulonephritis: a protective role for endothelial P-selectin in inflammation. , 1999, The Journal of clinical investigation.

[49]  B. Haynes,et al.  Wegener's granulomatosis: prospective clinical and therapeutic experience with 85 patients for 21 years. , 1983, Annals of internal medicine.

[50]  T. Watts,et al.  Molecular chaperones in antigen presentation. , 1995, Current opinion in immunology.

[51]  K. Tadokoro,et al.  Tolerance of NK and LAK activity for HLA class I-deficient targets in a TAP1-deficient patient (bare lymphocyte syndrome type I). , 1999, Human immunology.